Equity Overview
Price & Market Data
Price: $0.518
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $803,832,448
Volume: 0
Company Details
Employees: 135
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally. The company offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, a RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. Its product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for solid tumors; CS5001 for solid tumors and hematologic malignancies; and CS2013 and CS2015 for autoimmune diseases. The company was incorporated in 2015 and is headquartered in Suzhou, China.